Gilead Sciences Inc

Type: Company
Name: Gilead Sciences Inc
First reported 1 hour ago - Updated 1 hour ago - 1 reports

Motley Fool: Oct. 25, 2014

_ Ask the FoolPut Prices in ContextQ: Is a company priced at $50 per share in better shape than a company with a $10 share price? — W.D., Joliet, IllinoisA: Not necessarily. By itself, a company’s share price actually tells you very little, so never examine ... [Published St Augustine Herald - 1 hour ago]
First reported 18 hours ago - Updated 3 hours ago - 3 reports

Gilead Sciences : FDA Approvides Harvoni (Ledipasvir/Sofosbuvir)

Gilead Sciences recently reported that the U.S. Food and Drug Administration (FDA) has approved Harvoni (ledipasvir 90 mg/ sofosbuvir 400 mg), a once-daily single tablet regimen for the treatment of chronic hepatitis C genotype 1 infection in adults.Gilead ... [Published 4 Traders - 3 hours ago]
First reported 3 hours ago - Updated 3 hours ago - 1 reports

Pandora Media stock falls as growth flattens

Number of the day76.5 millionThat's how many active listeners Pandora Media reported in the third quarter. The Oakland Internet radio service said Thursday that user growth slowed to 5.2 percent, far below the 25 percent rate of a year earlier. Investors ... [Published San Francisco Chronicle - 3 hours ago]
First reported 9 hours ago - Updated 9 hours ago - 1 reports

Gilead Sciences Hits New 12-Month High at $111.47 (GILD)

Shares of Gilead Sciences (NASDAQ:GILD) reached a new 52-week high during mid-day trading on Friday , AmericanBankingNews.com reports. The stock traded as high as $111.47 and last traded at $110.06, with a volume of 9,627,668 shares traded. The stock ... [Published American Banking News - 9 hours ago]
First reported 15 hours ago - Updated 13 hours ago - 2 reports

Jim Cramer: Celgene, Gilead Leading Biotech Charge Higher

10/24/14 - 12:24 PM EDTNEW YORK ( TheStreet ) -- On Thursday, shares of Celgene ( CELG ) climbed 5.9% after beating revenue and EPS estimates. On Friday, the stock continued its move higher on what Cramer, the co-manager of the Action Alerts PLUS portfolio ... [Published TheStreet.com - 15 hours ago]
First reported 13 hours ago - Updated 13 hours ago - 5 reports

Friday Sector Leaders: Healthcare, Utilities

In afternoon trading on Friday, Healthcare stocks are the best performing sector, up 1.2%. Within the sector, Edwards Lifesciences (NYSE: EW) and Gilead Sciences (NASD: GILD) are two of the day's stand-outs, showing a gain of 11.0% and 3.7%, respectively. ... [Published Atlanta Journal And Constitution - 13 hours ago]
First reported 15 hours ago - Updated 15 hours ago - 1 reports

Stocks On the Move: Gigamon Inc, Gilead Sciences, Inc., and GoPro Inc

U.S. stocks are solidly higher this afternoon, as earnings from Microsoft Corporation (NASDAQ:MSFT) and Procter & Gamble Co (NYSE:PG) overshadow escalating concerns about Ebola. Among the equities making notable moves are IT concern Gigamon Inc (NYSE:GIMO), ... [Published Schaeffers Research - 15 hours ago]
First reported Oct 23 2014 - Updated 19 hours ago - 2 reports

When the claim of ‘innovation’ is simply higher prices

High prices fuel the fire of innovation – that’s the misleading explanation drug companies give for setting their prices at astronomical levels.  It’s also the explanation that Memorial Sloan Kettering’s Peter Bach, M.D., easily disproves in a new Forbes ... [Published Ahip Hi-Wire - Oct 24 2014]
First reported Oct 23 2014 - Updated Oct 23 2014 - 2 reports

Gilead Sciences, Vipshop Set Up Base Patterns

Now that the market is back in an uptrend, investors should look to buy stocks breaking out from bases. Gilead Sciences and Vipshop Holdings haven't broken out yet, but they are clearly two leaders in bases. Gilead Sciences (GILD) is in a lopsided consolidation ... [Published Town Hall - Oct 23 2014]
First reported Oct 23 2014 - Updated Oct 23 2014 - 3 reports

AHF to Gilead: Do Your Patriotic Duty and Lower Hep. C Drug Prices for Veterans

AIDS Healthcare Foundation (AHF) , the world’s largest AIDS organization and an outspoken advocate against runaway drug pricing for lifesaving HIV/AIDS and other medications, today called on Gilead Sciences, Inc…Click to Continue » ... [Published Fort Mills Times - Oct 23 2014]
First reported Oct 23 2014 - Updated Oct 23 2014 - 1 reports

Yale and Gilead Sciences extend cancer research collaboration

By Bill HathawayOctober 23, 2014The Yale School of Medicine has announced a three-year extension of a research collaboration with Gilead Sciences, Inc., which was formed in 2011 to discover novel cancer therapies. Under the terms of the initial agreement, ... [Published Yale University - Oct 23 2014]
First reported Oct 23 2014 - Updated Oct 23 2014 - 1 reports

Gilead Q3 Earnings Preview: Sovaldi Drives Another Brilliant Quarter

Gilead Sciences is expected to report upbeat earnings for the third quarter on Oct. 28, as it witnesses another high-growth quarter on the back of Sovaldi's salesPage 1 of 2Click Ticker to See live coverageGilead Sciences, Inc. ( GILD ) will release its ... [Published Bidness Etc - Oct 23 2014]

Quotes

...patients the potential for a cure in as little as eight weeks," said John C Martin , PhD, Chairman and Chief Executive Officer, Gilead Sciences . "Gilead is proud to have played a role in developing a once-daily therapy that is safe, simple and well tolerated. We are now working to ensure rapid and broad access to Harvoni."
...the U S is the shining star in the global growth constellation so that will be an important number from a psychological standpoint," McCarthy said. "I think it should be pretty good at 3.2 percent. The first estimate is always a bit of a wild card."
Merck : "Here's a company that's been a bellwether for big pharma." With a terrific quarter it can lift the old-line drug stocks, Cramer says
"This thing is a massively successful money machine. Why anybody would want to interrupt that I don't know" said Bill Smead, portfolio manager of the Smead Value Fund, which owns 357,000 Amgen shares

More Content

All (1787) | News (1344) | Reports (0) | Blogs (396) | Audio/Video (1) | Fact Sheets (7) | Press Releases (33)
sort by: Date | Relevance
Motley Fool: Oct. 25, 2014 [Published St Augustine Herald - 1 hour ago]
Gilead Sciences : FDA Approvides Harvoni (Ledip... [Published 4 Traders - 3 hours ago]
Pandora Media stock falls as growth flattens [Published San Francisco Chronicle - 3 hours ago]
Trading could get scary next week as Fed day looms [Published Yahoo! Malaysia - 7 hours ago]
Trading could get scary next week as Fed day looms [Published CNBC - 9 hours ago]
Jim Cramer's 'Mad Money' Recap: Here's Next Wee... [Published The Street Latest - 9 hours ago]
Cramer: Ebola, the Fed and earnings, oh my [Published Chicago Daily Herald - 9 hours ago]
Gilead Sciences Hits New 12-Month High at $111.... [Published American Banking News - 9 hours ago]
Economics of Ebola Pt. 2 [Published Investors Alley - 9 hours ago]
Cramer: Ebola, the Fed and earnings, oh my [Published CNBC - 10 hours ago]
Best And Worst ETFs Of The Week Amid Biotech... [Published Nasdaq - 10 hours ago]
Stocks Trade Higher Ahead of News-Heavy Weekend [Published Minyanville - 10 hours ago]
Best And Worst ETFs Of The Week Amid Biotech Br... [Published Benzinga.com - 11 hours ago]
Calendar: What investors need to know for the w... [Published Globe and Mail - 11 hours ago]
With AbbVie merger dead, Shire focuses on future [Published Boston Globe - 11 hours ago]
PREVIEW-Despite Third Point, low expectations f... [Published CNBC - 13 hours ago]
Friday Sector Leaders: Healthcare, Utilities [Published Atlanta Journal And Constitution - 13 hours ago]
Friday Sector Leaders: Healthcare, Utilities [Published TeleTrader.com - 13 hours ago]
Friday Sector Leaders: Healthcare, Utilities [Published Chicago Daily Herald - 13 hours ago]
Friday Sector Leaders: Healthcare, Utilities [Published Minyanville - 13 hours ago]
Friday Sector Leaders: Healthcare, Utilities [Published Forbes.com - 13 hours ago]
AHF To Gilead Sciences, Inc.: Do Your Patriotic... [Published BioSpace - 13 hours ago]
Fab Four - Got To Get You Into My Life [Published Seeking Alpha - 14 hours ago]
Bristol-Myers Tops Estimates as Sales From Key ... [Published Washington Post - 14 hours ago]
Stocks On the Move: Gigamon Inc, Gilead Science... [Published Schaeffers Research - 15 hours ago]
Earnings Expected to Increase for Gilead Sciences [Published Forbes.com - 15 hours ago]
New therapies create 'optimistic time' for HCV,... [Published Orthopedics Today - 15 hours ago]
ALS-008176 shows promise in healthy adults with... [Published Orthopedics Today - 15 hours ago]
Jim Cramer: Celgene, Gilead Leading Biotech Cha... [Published TheStreet.com - 15 hours ago]
Jim Cramer: Celgene, Gilead Leading Biotech Cha... [Published The Street Latest - 15 hours ago]
1 2 3 4 5 6 7 8 9 10 ...
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Gilead Sciences: Harvoni “Off to the Races” [Published BARRONS.com Stocks To Watch Today - 18 hours ago]
Gilead Sciences’ (GILD) new Hepatitis-C treatment Harvoni just hit the market–and it’s “off to the races,” says UBS analyst Matthew Roden and team. They explain: Scripts for Gilead’s Harvoni during the week ending October 17 were released today with total ...
Why Facebook and Twitter May Not Be Overvalued [Published The Simple Dollar - 20 hours ago]
Ellen’s famous Oscar selfie was retweeted over 2 million times, and Twitter didn’t pay a cent for the exposure. Photo: TheEllenShow It’s easy to write off social media stocks and their ludicrous valuations. Take Facebook (FB), which reports third-quarter ...
Gilead Sciences (GILD) Showing Bullish Technica... [Published MarketIntelligenceCenter.com - 20 hours ago]
MarketIntelligenceCenter.com’s patented algorithms have chosen the Dec. '14 $110.00 call for a couple of hedged-trading ideas on Gilead Sciences Inc (GILD). A traditional covered call on Gilead Sciences yields 7.23% (46.32% annualized, for comparison ...
Alexion Pharmaceuticals: Nice Earnings, Too Exp... [Published BARRONS.com Stocks To Watch Today - Oct 23 2014]
On a day when biotech stocks like Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN) and Celgene (CELG) are flying, few are flying higher than Alexion Pharmaceuticals (ALXN). Alexion has gained 7.1% after the biotech company reported a profit of ...
VC-backed ProNai adds five to senior management... [Published PE Hub Blog - Oct 23 2014]
ProNAi Therapeutics , a developer of nucleic acid therapeutics, has expanded its senior management team with five additions. Joining the firm are Dr. Angie You as chief business and strategy officer and head of commercial; Wendy Chapman as senior vice ...
1 2 3 4 5 6 7 8 9 10 ...

Audio/Video

sort by: Date | Relevance
The FDA Approves An Expensive New Hepatitis Drug [Published Wall Street Journal What's News - Oct 10 2014]
1

Press Releases

sort by: Date | Relevance
Critical Alerts For Tesla Motors, Tekmira Pharm... [Published Financial Services - Oct 15 2014]
Pre-market Biotech Picks - Gilead Sciences, Man... [Published Financial Services - Oct 14 2014]
Marketing Application Update, Acquisitions, Col... [Published Financial Services - Oct 10 2014]
Phase II IMPACT study initiated to evaluate Sim... [Published GlobeNewswire: Acquisitions News - Oct 10 2014]
Positive Study Results, Acquisitions, Drug Appr... [Published Financial Services - Sep 30 2014]
1 2 3 4 5 6 7
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.